Home' Australian Pharmacist : May 2011 Contents Vol. 30 -- May #05
Continuing Professional Development
The questions in this series are independently researched and compiled by PSA commissioned authors and peer reviewed.
Each question is worth 0.5 CPD credits.
knowledge in practice
Knowledge in practice
The challenge of applying what you
learn to pharmacy practice!
Knowledge in practice is designed
to be difficult and aims to make you
apply information from articles in
this month's Australian Pharmacist
and other suggested reading to the
questions below, just as you would
for a client/patient. is section
is not meant to be easy. ere are
no simple clear-cut answers to the
questions. e standard references
listed below may be of use when
answering the questions.
1. Sansom L (ed). Australian Pharmaceutical Formulary
and Handbook, 21st Ed. Canberra: Pharmaceutical
Society of Australia, 2009.
2. Rossi S (ed). Australian Medicines Handbook. Adelaide:
Australian Medicines Handbook Pty Ltd; 2011.
3. National Prescribing Service [online]. At: www.nps.org.au
4. Merck Manual of Diagnosis and Therapy [online].
5. Product information -- available from various
sources, e.g. MIMS, APP Guide or online on
6. Royal College of Pathologists of Australasia. RCPA
Manual [online]. At: www.rcpamanual.edu.au
7. Therapeutic Guidelines Series. eTG complete
[CD-ROM]. Melbourne: Therapeutic Guidelines Limited.
Through successful completion
of this activity, the learner will
demonstrate their ability to:
• Use readily available information
sources to access and select
relevant and up-to-date clinical
and practice-based information.
• Promote and contribute to the
optimal use of medicines.
• Address primary health needs
Competency standards (2010)
addressed: 4.2.1, 4.2.2, 4.2.3,
6.1.1, 6.1.2, 7.1.2, 7.1.3, 7.1.4, 7.2.2
Question 1. Ulcerative
Note: The Therapeutic Guidelines Series
are now listed within Pharmacy Board
of Australia Guideline 1, as a reference
which 'must be readily accessible and
should be accessed by pharmacists
during dispensing, clinical assessment,
reviewing and counselling processes'.
For this reason, the Therapeutic
Guidelines Series have now been added
to the list of standard references required
to answer the Knowledge in Practice
(KIP) questions. To successfully answer
the following question, pharmacists'
will need to refer to the Therapeutic
Fran, a young woman, brings a
prescription into your pharmacy for:
• prednisone 25 mg daily on a reducing
schedule over two weeks
• Salofalk tablets 500 mg three tablets
twice daily (previously prescribed
500 mg three times daily)
Fran was first diagnosed with
extensive ulcerative colitis by her
gastroenterologist about nine months
ago and was commenced on Salofalk
500 mg tablets, one three times a
day. Fran explains that her GP has just
diagnosed a moderate relapse of her
extensive ulcerative colitis and wants
her to start on prednisone to reduce the
acute inflammation. He has explained
that, due to the many long-term effects
of prednisone, it is important that she
'wean off the prednisone quickly'.
Her doctor has given her a repeat
prescription for Salofalk tablets, which
she will take long-term, at the increased
dose, to prevent exacerbations. Before
being diagnosed with ulcerative colitis
Fran was healthy with no medical
conditions. She tells you that, about
three years ago, she developed a rash
after taking Bactrim for a urinary tract
infection. As you are aware that the
latest version of the Gastrointestinal
Therapeutic Guidelines (version 5, 2011)
has just been released, you check that
the prescription her doctor has written is
consistent with the current guidelines.
After reviewing the new treatment
guidelines, which of the following options
is the MOST APPROPRIATE course
a) Contact the doctor and request that
he add cyclosporin to her therapy, to
prevent ulcerative colitis relapses.
Dispense the prescriptions for
prednisone and Salofalk tablets as
b) Contact the doctor to request
that he extend the tapering of the
prednisone from two weeks to
8--12 weeks, starting from the initial
dose of 25 mg daily. Dispense the
prescription for Salofalk tablets
c) Contact the doctor to request
that he increase the initial dose
of prednisone to 50 mg daily and
extend the taper from two weeks
to 8--12 weeks. Dispense the
prescription for Salofalk tablets as
d) Contact the doctor to request that
he change Fran from Salofalk to
Salazopyrin tablets 500 mg twice
daily. Dispense the prescription for
prednisone as written.
Question 2. Medicines and
Additional reference: Department
of Veterans Affairs. Therapeutic Brief
26: the impact of commonly used
medicines on urinary incontinence
[online]. Mar 2011 [accessed 29 Mar
2011]. At: http://tinyurl.com/apv30051a
Geoffrey, a regular customer in your
pharmacy, is aged in his mid 70s
and always enjoys a chuckle with the
pharmacy assistants as he waits for his
prescriptions. On this particular visit,
when he collects his prescriptions, he
nervously places a packet of men's
incontinence briefs on the counter to
purchase. You discreetly ask him about
this and he says that recently he has
been experiencing urinary leakage,
dribbling during urination and nocturia.
His regular medicines include enalapril
5 mg daily, metformin 500 mg three
times daily, paracetamol 1,000 mg
four times daily and esomeprazole
20 mg daily.
Links Archive June 2011 April 2011 Navigation Previous Page Next Page